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In this paper, we discuss common challenges in and
principles for conducting systematic reviews of genetic
tests. The types of genetic tests discussed are those
used to 1). determine risk or susceptibility in asymp-
tomatic individuals; 2). reveal prognostic information to
guide clinical management in those with a condition; or
3). predict response to treatments or environmental
factors. This paper is not intended to provide compre-
hensive guidance on evaluating all genetic tests. Rather,
it focuses on issues that have been of particular
concern to analysts and stakeholders and on areas that
are of particular relevance for the evaluation of studies
of genetic tests. The key points include:
& The general principles that apply in evaluating genetic
tests are similar to those for other prognostic or
predictive tests, but there are differences in how the
principles need to be applied or the degree to which
certain issues are relevant.
& A clear definition of the clinical scenario and an analytic
framework is important when evaluating any test,
including genetic tests.
& Organizingframeworksandanalytic frameworksare useful
constructs for approaching the evaluation of genetic tests.
& In constructing an analytic framework for evaluating a
genetic test, analysts should consider preanalytic, ana-
lytic, and postanalytic factors; such factors are useful
when assessing analytic validity.
& Predictive genetic tests are generally characterized by a
delayed time between testing and clinically important
events.
& Finding published information on the analytic validity
of some genetic tests may be difficult. Web sites (FDA
or diagnostic companies) and gray literature may be
important sources.
& In situations where clinical factors associated with risk
are well characterized, comparative effectiveness
reviews should assess the added value of using genetic
testing along with known factors compared with using
the known factors alone.
& For genome-wide association studies, reviewers should
determine whether the association has been validated in
multiple studies to minimize both potential confounding
and publication bias. In addition, reviewers should note
whether appropriate adjustments for multiple compar-
isons were used.
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W
ith recent advances in genotyping, it is expected that
whole genome sequencing will soon be available for
less than $1000. Consequently, the number of studies of
genetic tests will likely increase substantially, as will the
need to evaluate studies of genetic tests. The general
principles for evaluating genetic tests are similar to those
for interpreting other prognostic or predictive tests, but there
are differences in how the principles need to be applied and
the degree to which certain issues are relevant, particularly
when considering genetic test results that provide predictive
rather than diagnostic information.
This paper focuses on issues of particular concern to
analysts and stakeholders and areas of particular relevance
for the evaluation of studies of genetic tests. It is not
intended to provide comprehensive guidance on evaluating
all genetic tests. We reflect on genetic tests used to 1)
determine risk or susceptibility in asymptomatic individuals
(to identify individuals at risk for future health conditions,
such as BRCA1 and BRCA2 for breast and ovarian cancer);
2) reveal prognostic information to guide clinical manage-
ment and treatment in those with a condition (e.g.,
Oncotype Dx® for breast cancer recurrence, a test to
evaluate the tumor genome of surgically excised tumors
from patients with breast cancer); or 3) predict response to
treatments or environmental factors including diet (nutrige-
nomics), drugs (pharmacogenomics, such as CYP2C9 and
VKORC1 tests to inform warfarin dosing), infectious
S83agents, chemicals, physical agents, and behavioral factors.
We do not address genetic tests used for diagnostic purposes.
We address issues related to both heritable mutations and
somatic mutations (e.g., genetic tests for tumors).
Clinicians, geneticists, analysts, policymakers, and other
stakeholders may have varying definitions of what is
considered a “genetic test.” We have chosen to use a broad
definition in agreement with that of the Centers for Disease
Control and Prevention (CDC)-sponsored Evaluation of
Genomic Applications in Practice and Prevention (EGAPP)
and the Secretary’s Advisory Committee on Genetics,
Health, and Society,
1 namely: “A genetic test involves the
analysis of chromosomes, deoxyribonucleic acid (DNA),
ribonucleic acid (RNA), genes, or gene products (e.g.,
enzymes and other proteins) to detect heritable or somatic
variations related to disease or health. Whether a laboratory
method is considered a genetic test also depends on the
intended use, claim, or purpose of a test.”
1 The same
technologies are used for diagnostic and predictive genetic
tests; it is the intended use of the test result that determines
whether it is a diagnostic or predictive test.
In this paper, we discuss principles for addressing chal-
lenges related to developing the topic and structuring a
genetic test review (context and scoping), as well as
performing the review. This paper is meant to complement
the Methods Guide for Comparative Effectiveness Reviews.
2
We do not attempt to reiterate the challenges and principles
described in earlier sections of this Medical Test Methods
Guide, but focus instead on issues of particular relevance for
evaluating studies of genetic tests. Although we have written
this paper to serve as guidance for the Agency for Healthcare
Research and Quality (AHRQ) Evidence-based Practice
Centers (EPCs), we also intend for this to be a useful
resource for other investigators interested in conducting
systematic reviews on genetic tests.
COMMON CHALLENGES
Genetic tests are different from other medical tests in their
relationship to the outcomes measured. Reviewers need to
take into account the penetrance of the disease, time lag to
outcomes, variable expressivity, and pleiotropy (as defined
below). These particular aspects of genetic tests result in
specific actions at various stages of planning and performing
the review. Both single-gene and polygenic disorders are
known. Single gene disorders are the result of a single mutated
gene and may be passed on to subsequent generations in
various well-described ways (i.e., autosomal dominant, auto-
somal recessive, X-linked). Polygenic disorders are the result
of the combined action of more than one gene and are not
inherited by simple Mendelian patterns. Some examples
include heart disease and diabetes. Some of the terms
described below (penetrance, variable expressivity, and plei-
otropy) are generally used to describe single-gene disorders.
Penetrance
Evaluations of predictive genetic tests should always consider
penetrance, defined as “the proportion of people with a
particular genetic change who exhibit signs and symptoms of
ad i s o r d e r . ”
3 Penetrance is a key factor in determining the
future risk of developing disease and assessing the overall
clinical utility of predictive genetic tests. Sufficient data to
determine precise estimates of penetrance are sometimes
lacking.
4,5 This can be due to the lack of reliable prevalence
data or a lack of long-term outcomes data. In such cases,
determining the overall clinical utility of a genetic test is
difficult. In some cases, modeling with sensitivity analyses
can be helpful to develop estimates.
4
Time Lag
The time lag between genetic testing and clinically
important events should be assessed in critical appraisal of
studies of such tests. Whether the duration of studies and
follow-up are sufficient to characterize the relationship
between positive tests and clinical outcomes are important
considerations. In addition, it should be determined whether
or not subjects have reached the age beyond which clinical
expression would be likely.
Variable Expressivity
Variable expressivity refers to the range of severity of the
signs and symptoms that can occur in different people with
the same condition.
3 For example, the features of hemo-
chromatosis vary widely. Some individuals have mild
symptoms, while others experience life-threatening compli-
cations such as liver failure. The degree of expressivity
should be considered in the evaluation of genetic tests.
Pleiotropy
Pleiotropy occurs when a single gene influences multiple
phenotypic traits. For example, the genetic mutation
causing Marfan syndrome results in cardiovascular, skeletal,
and ophthalmologic abnormalities. Similarly, BRCA muta-
tions can increase the risk of a number of cancers, including
breast, ovarian, prostate, and melanoma.
Other Common Challenges
Another common challenge in evaluating predictive genetic
tests is that direct evidence for the impact of the test results
on health outcomes is often lacking. The evidence base may
often be too limited in scope to evaluate the clinical utility
of the test. In addition, it is often difficult to find published
information on various aspects of genetic tests, especially
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developed tests (LDT) are regulated by the Centers for
Medicare & Medicaid Services (CMS) Clinical Laboratory
Improvement Act (CLIA) regulations for clinical laborato-
ries. CLIA does not require clinical validation and many
LDTs have had no clinical validation or clinical utility
studies.
Genetic tests also have a number of technical issues that
are particularly relevant to assessing their analytic validity.
These technical issues may differ according to the type of
genetic test and may influence the interpretation of a genetic
test result. Technical issues may also differ depending on
the specimen being tested. For example, there are different
considerations when assessing tumor genomes as opposed
to human genomes.
Common challenges arise when attempting to use genetic
tests to determine susceptibility or risk in asymptomatic
individuals. The utility of such tests may depend on the
ability of respondents, such as the patient or their relative,
to report and identify certain clinical factors. For instance, if
patients cannot accurately recall the family history of a
heritable disease, it can be difficult to assess their risk of
developing the disease.
Finally, statistical issues must be taken into account when
evaluating studies of genetic tests. For example, genetic test
results are often derived from analytically complex studies
that have undergone a very large number of statistical tests,
creating a high risk of Type I error (i.e., a spurious
association is deemed significant).
PRINCIPLES FOR ADDRESSING THE CHALLENGES
(BOX 11-1)
Principle 1: Use an Organizing Framework
Appropriate for Genetic Tests
Organizing frameworks for evaluating genetic tests have
been developed by the United States Preventive Services
Task Force (USPSTF), the CDC, and EGAPP.
1,6,7 The
model endorsed by the EGAPP initiative
1 was based on a
previous Task Force report
8 and developed through a
CDC-sponsored project, which piloted an evidence eval-
uation framework that applied the following three criteria:
1) analytic validity (technical accuracy and reliability), 2)
clinical validity (ability to detect or predict an outcome,
disorder, or phenotype), and 3) clinical utility (whether
use of the test to direct clinical management improves
patient outcomes). A fourth criterion was added: 4)
ethical, legal, and social implications.
6 The ACCE model
(Analytic validity, Clinical validity, Clinical utility, and
Ethical, legal and social implications) includes a series of
44 questions that are useful for analysts in defining the
scope of a review, as well as for critically appraising
studies of genetic tests (Table 1). The initial seven
questions help to guide an understanding of the disorder,
the setting, and the type of testing. A detailed description
of the methods of the EGAPP Working Group is
published elsewhere.
1
Principle 2: Develop Analytic Frameworks
to Reflect the Predictive Nature of Genetic
Tests and Incorporate Appropriate Outcomes
It is important to have a clear definition of the clinical
scenario and analytic framework when evaluating any test,
including a predictive genetic test. Prior to performing a
review, analysts should develop clearly defined key
questions and understand the needs of decision makers
and the context in which the tests are used. They should
consider whether this is a test used for determining future
risk of disease in asymptomatic individuals, establishing
prognostic information that will influence treatment
decisions, or predicting response to treatments (either
effectiveness or harms)—or used for some other purpose.
They should clarify the type of specimens used for the
genetic test under evaluation (i.e., patient genome or tumor
Box 11-1. Principles for Addressing Common Challenges when Evaluating Genetic Tests used as  
Predictive Indicators
Principle 1: Use an Organizing Framework Appropriate for Genetic Tests
Principle 2: Develop Analytic Frameworks to Reflect the Predictive Nature of Genetic Tests and Incorporate   
Appropriate Outcomes
Principle 3: Search Databases Appropriate for Genetic Tests
Principle 4: Consult with Experts to Determine which Technical Issues are Important to Address in   
Assessing Genetic Tests
Principle 5: Distinguish Between Functional Assays and DNA-based Assays to Determine Important  
Technical Issues
Principle 6: Evaluate Case-control Studies Carefully for Potential Selection Bias
Principle 7: Determine the Added Value of the Genetic Test Over Existing Risk Assessment Approaches  
Principle 8: Understand Statistical Issues of Particular Relevance to Genetic Tests
S85 Jonas et al.: Systematic Reviews of Genetic Tests as Predictive Indicators JGIMgenome). The PICOTS typology (Patient population,
Intervention, Comparator, Outcomes, Timing, Setting)
should be clearly described as it will inform the develop-
ment of the analytic framework and vice versa.
In constructing an analytic framework, it may be useful
for analysts to consider preanalytic, analytic, and postana-
lytic factors particularly applicable to genetic tests (de-
scribed later in this paper), as well as the key outcomes of
interest. Analytic frameworks should incorporate the factors
and outcomes of greatest interest to decision makers.
Figure 1 illustrates a generic analytic framework for
evaluating predictive genetic tests that can be modified as
necessary for various situations.
In addition to effects on family members, psycholog-
ical distress and possible stigmatization or discrimination
are potential harms that may result from predictive genetic
tests, particularly those test results that predict probability
of disease occurring with a high likelihood, especially if
no proven preventive or ameliorative measures are
available. For these potential harms, analysts should take
into account whether the testing is for inherited or
acquired genetic mutations since these factors influence
the potential for harms. In addition, whether the condition
related to the test is multifactorial or follows classic
Mendelian inheritance will affect the potential for these
harms.
Other important outcomes to consider when evaluating
genetic tests include, but are not limited to, cost, quality of
life, long-term morbidity, and indirect impact. Genetic tests
may have an impact on decisions that are difficult to
Table 1. ACCE Model Questions for Reviews of Genetic Tests
6
Element Questions
Disorder/setting 1. What is the specific clinical disorder to be studied?
2. What are the clinical findings defining this disorder?
3. What is the clinical setting in which the test is to be performed?
4. What DNA test(s) are associated with this disorder?*
5. Are preliminary screening questions employed?
6. Is it a stand-alone test or is it one of a series of tests?
7. If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are
only some tests performed on the basis of other results (series)?
Analytic validity 8. Is the test qualitative or quantitative?
9. How often is the test positive when a mutation is present?*
10. How often is the test negative when a mutation is not present?*
11. Is an internal quality control program defined and externally monitored?
12. Have repeated measurements been made on specimens?
13. What is the within-and between-laboratory precision?
14. If appropriate, how is confirmatory testing performed to resolve false positive results in a timely manner?
15. What range of patient specimens have been tested?
16. How often does the test fail to give a usable result?
17. How similar are results obtained in multiple laboratories using the same, or different technology?
Clinical validity 18. How often is the test positive when the disorder is present?
19. How often is the test negative when a disorder is not present?
20. Are there methods to resolve clinical false positive results in a timely manner? 21. What is the
prevalence of the disorder in this setting?
22. Has the test been adequately validated on all populations to which it may be offered?
23. What are the positive and negative predictive values?
24. What are the genotype/phenotype relationships?*
25. What are the genetic, environmental or other modifiers?*
Clinical utility 26. What is the natural history of the disorder?
27. What is the impact of a positive (or negative) test on patient care?
28. If applicable, are medical tests available?
29. Is there an effective remedy, acceptable action, or other measurable benefit?
30. Is there general access to that remedy or action?
31. Is the test being offered to a socially vulnerable population?
32. What quality assurance measures are in place?
33. What are the results of pilot trials?
34. What health risks can be identified for follow-up testing and/or intervention?
35. What are the financial costs associated with testing?
36. What are the economic benefits associated with actions resulting from testing?
37. What facilities/personnel are available or easily put in place?
38. What educational materials have been developed and validated and which of these are available?*
39. Are there informed consent requirements?*
40. What methods exist for long term monitoring?
41. What guidelines have been developed for evaluating program performance?
Ethical, legal, and
social implications
42. What is known about stigmatization, discrimination, privacy/confidentiality and personal/family social issues?*
43. Are there legal issues regarding consent, ownership of data and/or samples, patents, licensing,
proprietary testing, obligation to disclose, or reporting requirements?*
44. What safeguards have been described and are these safeguards in place and effective?*
Abbreviations: ACCE = Analytic validity, Clinical validity, Clinical utility, and Ethical, legal and social implications; DNA = deoxyribonucleic acid
*Many of the questions in this Table (or variants of the questions) are relevant for evaluating most medical tests, not just genetic tests. Those with an
asterisk (questions 4, 9, 10, 24, 25, 38, 39, 42, 43, and 44) are only relevant for evaluating genetic tests or may require extra scrutiny when
evaluating genetic tests
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pregnancy.
Depending on the context, the impact of genetic testing
on family members may be important, particularly in cases
that involve testing for heritable conditions. One approach
to including family members in the analytic framework is
illustrated in Figure 2.
Principle 3: Search Databases Appropriate for
Genetic Tests
The Human Genome Epidemiology Network (HuGE Net)
Web site can provide a helpful supplement to searches, as it
includes many meta-analyses of genetic association studies
as well as a source called the HuGE Navigator that can
Figure 1. Generic analytic framework for evaluating predictive genetic tests.
Figure 2. Generic analytic framework for evaluating predictive genetic tests when the impact on family members is important.
S87 Jonas et al.: Systematic Reviews of Genetic Tests as Predictive Indicators JGIMidentify all types of available studies related to a genetic
test.
9
When assessing the gray literature, U.S. Food and Drug
Administration (FDA)-approved test package inserts con-
tain summaries of the analytic validity data. Package inserts
are available on the FDA and manufacturer Web sites.
Laboratory-developed tests do not require FDA clearance,
and there is no requirement for publicly available data on
analytic validity. When there are no published data on
analytic validity of a genetic test, the external proficiency
testing program carried out jointly by the American College
of Medical Genetics (ACMG) and the College of American
Pathologists (CAP) can be useful in establishing the degree
of laboratory-to-laboratory variability, as well as some sense
of reproducibility.
10–12 Other potentially useful sources of
unpublished data include conference publications from
professional societies (e.g., the College of American
Pathologists), the GeneTests Web site (www.genetests.org),
the Association for Molecular Pathology Web site
(www.amp.org), CDC programs (e.g., the Genetic Testing
Reference Materials Coordination Program and the New-
born Screening Quality Assurance Program), and interna-
tional proficiency testing programs.
13
An AHRQ “horizon scan” found two databases—the
LexisNexis® database (www.lexisnexis.com) and Cambridge
Healthtech Institute (CHI) (www.healthtech.com/)—that had
high utility in identifying genetic tests in development for
clinical cancer care. A number of others had low-to-moderate
utility, and some were not useful.
14
Principle 4: Consult with Experts to Determine
which Technical Issues are Important
to Address in Assessing Genetic Tests
There are a number of technical issues related to analytic
validity that can influence the interpretation of a genetic test
result, including preanalytic, analytic, and postanalytic
factors.
15,16 In general, preanalytic steps are those in-
volved in obtaining, fixing or preserving, and storing
samples prior to staining and analysis. Important analytic
variables include the type of assay chosen and its
reliability, types of samples, the specific analyte investi-
gated, specific genotyping methods, timing of sample
analysis, and complexity of performing the assay. Post-
analytic variables relate to the complexity of interpreting
the test result, variability from laboratory to laboratory,
and quality control.
15,16 Comparative effectiveness review
teams should include or consult with molecular patholo-
gists, geneticists, or others familiar with the issues related
to the process of performing and reporting genetic tests to
determine which of these technical issues are pertinent for
a given review. Table 2 summarizes some of the
preanalytic, analytic, and postanalytic questions that should
be addressed.
For genetic testing of tumor specimens, it is important
to understand that the tumor genome may be in a dynamic
state, with mutations emerging over time (e.g., due to drug
exposure or disruption of cellular repair). Tumor speci-
mens will often contain normal cells from the patient as
well as tumor cells. To accurately assess for somatic
mutations using tumor specimens, particular strategies
may be needed, such as enriching samples for tumor cells
(e.g., by microscopic evaluation and dissection of tumor
cells).
Principle 5: Distinguish Between Functional
Assays and DNA-based Assays to Determine
Important Technical Issues
Some studies may utilize DNA-based assays whereas others
may utilize functional assays with different sensitivities and
specificities. Functional assays, in which a substrate or
Table 2. Questions for Assessing Preanalytic, Analytic, and Postanalytic Factors for Evaluating Predictive Genetic Tests*
Element Questions
Preanalytic What patient characteristics are relevant to the analytic validity of the test (e.g., age, sex, ethnicity,
race, ancestry, parental history of consanguinity, family health history)?
What types of samples were used?
How were samples obtained?
How were samples handled and stored prior to analysis?
Analytic What type of assay was used? What is the reliability of the assay?
What specific analyte was investigated (e.g., specification of which alleles, genes, or biochemical analytes were evaluated)?
For DNA-based tests, what is the definition of the genotype investigated?
Did the study test for all potentially relevant alleles?
For DNA-based tests, what genotyping methods were used?
When were samples analyzed (compared to when they were collected)?
Was the timing of analysis equal for both study groups (if applicable)?
How often does the test give a usable result (what is the “call rate”)?
Postanalytic How are the test results interpreted and applied? How complex is interpretation and application?
What quality control measures were used? Were repeated measurements made on specimens?
How reproducible is the test over time? How reproducible is the test when repeated in the same
patient multiple times? How reproducible is the test from laboratory to laboratory?
*Portions of this Table were adapted from Burke et al., 2002
15 and Little et al., 2002.
16
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genetic polymorphism is measured, may have the advantage
of showing potentially more important information than the
presence of the genetic polymorphism itself. However, they
may be affected by a number of factors and do not
necessarily reflect the polymorphism alone. Unmeasured
environmental factors, other genetic polymorphisms, and
various disease states may influence the results of functional
assays. In addition, functional assays that measure enzyme
activity are taken at a single point in time. Depending on the
enzyme and polymorphism being evaluated, the variation in
enzyme activity over time should be considered in critical
appraisal. Inconsistent results between studies using DNA-
based molecular methods and those using phenotypic
assays have been reported.
16–18
For DNA-based tests, a variety of sample sources are
available (e.g., blood, cheek swab, hair) that should
hypothetically result in identical genotype results.
16,19–23
However, DNA may be more difficult to obtain and purify
from some tissues than from blood, particularly if the
tissues have been fixed in paraffin versus fresh samples
(DNA extraction from formalin-fixed tissue is difficult, but
sometimes possible).
16 Some studies utilize different sour-
ces of DNA for cases and controls, introducing potential
measurement bias from differences in the ease of technique
and test accuracy. Extraction of DNA from tumors in
oncology studies may raise additional issues that influence
analytic validity, including the quantity of tissue, admixture
of normal and cancerous tissue, amount of necrosis, timing
of collection, and storage technique (e.g., fresh, frozen,
paraffin, formalin).
16
When evaluating DNA-based molecular tests, the
complexity of the test method, laboratory-to-laboratory
variability, and quality control should be assessed. A
number of methods are available for genotyping single
nucleotide polymorphisms that vary in complexity and
potential for polymorphism misclassification.
16,24–26 Con-
sidering laboratory reporting of internal controls and
repetitive experiments can be useful in assessment of
overall analytic validity. The method of interpreting test
results may influence complexity as well. For example,
some tests require visual inspection of electrophoresis
Figure 3. Analytic framework for evidence gathering on CYP450 genotype testing for SSRI treatment of depression. Abbreviation: SSRI =
selective serotonin reuptake inhibitor. Numbers in this figure represent the research questions addressed in the systematic review:45 1
(overarching question): Does testing for cytochrome P450 (CYP450) polymorphisms in adults entering selective serotonin reuptake inhibitor
(SSRI) treatment for non-psychotic depression lead to improvement in outcomes, or are testing results useful in medical, personal, or public
health decisionmaking? 2: What is the analytic validity of tests that identify key CYP450 polymorphisms? 3a: How well do particular
CYP450 genotypes predict metabolism of particular SSRIs? Do factors such as race/ethnicity, diet, or other medications, affect this
association? 3b: How well does CYP450 testing predict drug efficacy? Do factors such as race/ethnicity, diet, or other medications, affect this
association? 3c: How well does CYP450 testing predict adverse drug reactions? Do factors such as race/ethnicity, diet, or other medications,
affect this association? 4a: Does CYP450 testing influence depression management decisions by patients and providers in ways that could
improve or worsen outcomes? 4b: Does the identification of the CYP450 genotypes in adults entering SSRI treatment for non-psychotic
depression lead to improved clinical outcomes compared to not testing? 4c: Are the testing results useful in medical, personal or public
health decisionmaking? 5: What are the harms associated with testing for CYP450 polymorphisms and subsequent management options?
S89 Jonas et al.: Systematic Reviews of Genetic Tests as Predictive Indicators JGIMgels. Inter-observer variability should be considered for
such tests.
16,27
Principle 6: Evaluate Case-Control Studies
Carefully for Potential Selection Bias
In critical appraisal of any case-control study, it is
important to determine whether cases and controls were
selected from the same source population. In the case of
genetic studies, the geographic location of the population
does not suffice. Rather, having cases and controls
matched for ethnicity/race or ancestry is important since
the frequencies of DNA polymorphisms vary from
population to population (i.e., population stratification).
It has been noted that many case-control studies of gene-
disease associations have selected controls from a popu-
lation that does not represent the population from which
the cases arose.
16,17,28–30 In general, only nested case-
control studies could have low enough potential for
selection bias to provide reliable information.
Principle 7: Determine the Added Value
of the Genetic Test over Existing Risk
Assessment Approaches
For some scenarios, a number of clinical factors associated
with risk assessment or susceptibility may already be well
characterized. In such cases, comparative effectiveness
reviews should determine the added value of using genetic
testing along with known factors compared with using the
known factors alone. For example, age, sex, smoking,
hypertension, diabetes, and cholesterol are all well-estab-
lished risk factors for cardiovascular disease. Risk stratifica-
tion of individuals to determine cholesterol-lowering targets
is based on these factors.
31 Assessment of newly identified
polymorphisms—such as those described on chromosome
9p21
32—that may confer increased risk of cardiovascular
disease and have potential implications for medical inter-
ventions should be evaluated in the context of these known
risk factors. In this scenario, investigators should determine
the added value of testing for polymorphisms of chromo-
some 9p21 in addition to known clinical risk factors.
Multiple polymorphisms may be associated with risk of
disease, prognosis, or prediction of drug response. In such
cases, the effect of multiple polymorphisms can be explored
using a multiple regression model. Then, prospective
studies would usually be needed to determine whether the
model including the genetic tests has clinical utility. For
example, VKORC1 and CYP2C9 genotypes have been
associated with warfarin dose requirements in multiple
regression models. In order to determine whether tests for
VKORC1 and CYP2C9 have clinical utility, studies would
need to compare the use of a prediction model that contains
the genetic tests in combination with known clinical factors
that affect warfarin dose (e.g., age, BMI) with the use of
clinical factors alone.
33–35
Principle 8: Understand Statistical Issues
of Particular Relevance to Genetic Tests
Hardy–Weinberg Equilibrium. In population genetics,
most allele distributions follow a usual distribution,
known as Hardy–Weinberg equilibrium (HWE). Genetic
association studies should generally report whether the
frequencies of the alleles being evaluated follow HWE.
There are a number of reasons that distributions may
deviate from HWE, including new mutations, selection,
migration, genetic drift, and inbreeding.
36 In addition, when
numerous polymorphisms are tested for associations with
diseases or outcomes, as in many genome-wide association
studies, many of them (5%) will deviate from HWE based
on chance alone (related to multiple testing).
37 Although it
is not specific and possibly not sensitive, deviation from
HWE may be a clue to bias and genotyping error.
37
Analysts should consider whether studies have tested for
and reported HWE. A more detailed discussion of this topic
as it relates to genetic association studies has been
published elsewhere.
36,37
Sample Size Calculations. When assessing internal validity
of studies, it is important to assess whether sample size
calculations appropriately accounted for the number of variant
alleles and the prevalence of variants in the population of
interest. This is particularly relevant for pharmacogenomic
studies evaluating the functional relevance of genetic
polymorphisms.
38 Such studies often enroll an insufficient
number of subjects to account for the number of variant
alleles and the prevalence of variants in the population.
38
Genetic Association Studies and Multiple Comparisons.
Genetic test results are sometimes derived from analytically
complex studies that have undergone a very large number
of statistical tests. These may be in the form of genome-
wide association studies searching for associations between
a huge number of genetic polymorphisms and health
conditions. Such association studies may launch further
understanding of the importance of genetics in relation to a
variety of health conditions but should generally be used to
generate hypotheses rather than to test hypotheses or to
confirm cause-effect relationships.
16 Close scrutiny should
be applied to ensure that the evidence for the association
has been validated in multiple studies to minimize both
potential confounding and potential publication bias
issues. In addition, reviewers should note whether
appropriate adjustments for multiple comparisons were
used. Many recommend using a P value of less than 5×10
−8
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studies.
37,39,40 Other approaches include assessing the false
positive report probability and controlling the false discovery
rate.
41–43
When a genetic mutation associated with increased risk is
present, evaluating potential causality can be difficult as
many other factors may influence associations. These
include environmental exposures, behaviors, and other
genes. Many genetic variants identified that are thought to
influence susceptibility to diseases are associated with low
relative and absolute risk.
16,44 Thus, exclusion of non-
causal explanations for associations and consideration of
potential confounders are central to critical appraisal of such
associations. It may also be important to explore biologic
plausibility (e.g., from in vitro studies) to help support or
oppose theories of causation.
16
Overlapping Data Sets. Be cautious of publications that
report prevalence estimates for genetic variants that have
actually arisen from overlapping data sets.
16 For example,
genome-wide association studies or other large
collaborative efforts, such as the International Warfarin
Pharmacogenomics Consortium, may pool samples of
patients that were previously included in other published
studies.
3 To the degree possible, investigators should
identify overlapping data sets and avoid double-counting.
It may be useful to organize evidence tables by study time
period and geographic area to identify potential overlapping
data sets.
16
Assessing Tumor Genetics. As mentioned under Principle
4, it is important to understand that a tumor genome may be
in a dynamic state. In addition, tumor specimens will often
contain normal cells from the patient. The characteristics of
the specimen will influence the sensitivity and operating
characteristics of the test. Tests with greater sensitivity may
be required when specimens contain both normal cells and
tumor cells.
ILLUSTRATIONS
Since the completion of the Human Genome Project, the
Hap Map project, and related works, there have been a
great number of publications describing the clinical
validity of genetic test results (e.g., gene-disease associa-
tions), but far fewer studies of the clinical utility. A review
of genetic testing for cytochrome P450 polymorphisms in
adults with depression treated with selective serotonin
reuptake inhibitors (SSRIs) developed an analytic frame-
work and five corresponding key questions which, taken
together, provide an example of a well-defined predictive
genetic test scenario that explores a potential chain of
evidence relating to intermediate outcomes (Figure 3).
45
The authors found no prospective studies with clinical
outcomes that used genotyping to guide treatment. They
constructed a chain of questions to assess whether
sufficient indirect evidence could answer the overarching
question by evaluating the links between genotype and
metabolism of SSRIs (phenotype), metabolism and SSRI
efficacy, and metabolism and adverse drug reactions to
SSRIs.
An EPC report on HER2 testing to manage patients with
breast cancer and other solid tumors provides a detailed
assessment of challenges in conducting a definitive evaluation
of preanalytic, analytic, and postanalytic factors when there is
substantial heterogeneity or lack of available information
related to the methods of testing.
46 The authors noted that it
had been only very recently that many aspects of HER2
assays were standardized, and that the effects of widely
varying testing methods could not be isolated. Thus, they
approached this challenge by providing a narrative review for
their first key question (What is the evidence on concordance
and discrepancy rates for methods [e.g., FISH, IHC, etc.] used
to analyze HER2 status in breast tumor tissue?).
Additional considerations arise when evaluating ge-
netic test results used to determine susceptibility or risk in
asymptomatic individuals. The utility of such tests may
depend on the ability of patients and providers to report
and identify certain clinical factors. For example, a review
of genetic risk assessment and BRCA mutation testing
underscores the importance of accurately determining
family history.
4,47 The analytic framework begins by
classifying asymptomatic women into high, moderate, or
average risk categories. This is a good example of
incorporating a key preanalytic factor (family history),
that has an important influence on analytic validity. Tests
for BRCA mutations may be used to predict the risk for
breast and ovarian cancer in high-risk women (i.e., those
with a family history suggesting increased risk). However,
because we do not know all of the genes that contribute to
hereditary breast and ovarian cancer and because analytic
methods to detect mutations in the known genes are not
perfect, population-based testing for hereditary suscepti-
bility to breast and ovarian cancer is currently not an
appropriate strategy. Rather, family history-based testing is
the paradigm that is recommended to guide the use of
BRCA testing.4, 47
Thus, family history is a genetic/genomics tool that is
used to 1) identify people with possible inherited disease
susceptibilities, 2) guide genetic testing strategies, 3) help
interpret genetic test results, and 4) assess disease risk.
The ability of providers to accurately determine a family
history that confers increased risk is a key prerequisite to
the utility of BRCA mutation and other predictive genetic
testing. It is sometimes difficult for people to accurately
recall the presence of a condition in their relatives.
Sensitivity and specificity of self-reported family history




Analysts should understand common challenges, and apply
the principles for addressing those challenges, when
conducting systematic reviews of genetic tests used as
predictive indicators. Key points include:
1) The general principles that apply in evaluating genetic
tests are similar to those for other prognostic or
predictive tests, but there are differences in how the
principles need to be applied or the degree to which
certain issues are relevant.
2) A clear definition of the clinical scenario and an
analytic framework is important when evaluating any
test, including genetic tests.
3) Organizing frameworks and analytic frameworks are
useful constructs for approaching the evaluation of
genetic tests.
4) In constructing an analytic framework for evaluating a
genetic test, analysts should consider preanalytic,
analytic, and postanalytic factors; such factors are
useful when assessing analytic validity.
5) Predictive genetic tests are generally characterized by a
delayed time between testing and clinically important
events.
6) Finding published information on the analytic validity
of some genetic tests may be difficult. Web sites (FDA
or diagnostic companies) and gray literature may be
important sources.
7) In situations where clinical factors associated with risk
are well characterized, comparative effectiveness
reviews should assess the added value of using genetic
testing along with known factors compared with using
the known factors alone.
8) For genome-wide association studies, reviewers should
determine whether the association has been validated in
multiple studies to minimize both potential confound-
ing and publication bias. In addition, reviewers should
note whether appropriate adjustments for multiple
comparisons were used.
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